DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp.(Nasdaq:DYAX) announced today positive topline results from itsPhase 3, placebo-controlled trial, EDEMA3, for its lead productcandidate DX-88 (ecallantide), for hereditary angioedema (HAE). Awebcast presentation of the EDEMA3 data is scheduled for Tuesday,April 17, 2007 at 12:30 p.m. ET. DX-88, an internally discovered, recombina...Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
Company anticipates second quarter BLA filing for C1-inhibitorreplacement therapy NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. (Lev) today announced positive results fromits pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH)for the acute treatment of hereditary angioedema (HAE). In theacute study, which is part of the company's CHANGE trials(C1-...